Epilepsy Course and Developmental Trajectories in STXBP1-DEE

Ganna Balagura1, Julie Xian1, Antonella Riva1

  • 1Pediatric Neurology and Muscular Diseases Unit (G.B., A. Riva, E.A., C. Minetti, V.S., M.S., A.A., M.S.V., P. Striano), IRCCS "G. Gaslini" Institute, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (G.B., A. Riva, E.A., C. Minetti, V.S., M.S., A.A., M.S.V., P. Striano), University of Genoa, Italy; Department of Functional Genomics (G.B., R.T.), Center for Neurogenomics and Cognitive Research (CNCR), Vrije Universiteit (VU) Amsterdam, the Netherlands; Division of Neurology (D., I.H.), Children's Hospital of Philadelphia; The Epilepsy NeuroGenetics Initiative (ENGIN) (D., I.H.), Children's Hospital of Philadelphia; Department of Biomedical and Health Informatics (DBHi) (D., I.H.), Children's Hospital of Philadelphia, PA; Child Neuropsychiatry Unit (F. Marchese), Arnas Civico Di Cristina, Palermo, Italia; Edmomd and Lilly Safra Pediatric Hospital (B.B.Z., M. Tzadok), Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel; Clínica Integral de Epilepsia Infanto-Juvenil (L.R.), Santiago, Chile; Division of Pediatric Neurology (D.S.), Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas and Children's Medical Center of Dallas, TX; Child Neurology and Psychiatry Unit (P.A., L.G.), Spedali Civili, Brescia; Department of Developmental Neuroscience (G.A., A.F.), IRCCS Stella Maris, Calambrone, Pisa; Unit of Medical Genetics (S.B., Francesca Madia, M.I., P. Scudieri, F.Z.), IRCCS Giannina Gaslini Institute, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genova; Epilepsy Center (F.B., G. Capovilla), Department of Child Neuropsychiatry, ASST Mantova, Mantua; Pediatric Neurology Unit (A.B., T.M., A. Parmeggiani, A. Russo), IRCCS Istituto delle Scienze Neurologiche di Bologna; UO Pediatria Cava de Tirreni (M.B.), AOU "S.Giovanni di Dio e Ruggi d'Aragona" Salerno; Child Neuropsychiatry (G. Cantalupo, E.F.), Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona; Fondazione Poliambulanza Brescia Italy (G. Capovilla); Department of Child Neuropsychiatry (E.C., C. Marini), G. Salesi Children's Hospital, University of Ancona; Epilepsy Center-Child Neuropsychiatric Unit (V.C., A. Vignoli), ASST Santi Paolo e Carlo, Milan; Department of Neuroscience (A.C.), Odontostomatology and Reproductive Sciences, Federico II University of Naples; Neuropathophysiology Unit (R.D.), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; University of Ferrara (R.F.), Clinical and Experimental Medicine, Pediatrics Ferrara, IT; UOC Laboratorio di Genetica Umana (E.G.), IRCCS Istituto Giannina Gaslini; Department of Neurosciences (T.G., L.N.), Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health, University of Genoa; Unit of Child Neuropsychiatry (T.G.), Department of Medical and Surgical Neuroscience and Rehabilitation, IRCCS Istituto Giannina Gaslini, Genova; Neurological Clinic (S.L.), Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona; Child Neuropsychiatry (M.M.M.), Epilepsy Center, Department of Medical and Surgical Neuroscience and Rehabilitation, IRCCS Istituto Giannina Gaslini, Genova; Paediatric Neurology Unit (M.M.), Department of Pediatrics, Children's Hospital Vittore Buzzi, Milan; Child Neuropsychiatry (A. Papa), Maggiore della Carità University Hospital Novara; Child Neurology and Psychiatry Unit (A. Parmeggiani), Infermi Hospital, AUSL Romagna, Rimini, Italy; Child Neurology and Psychiatry (T.P.), Neuroscience Department, Children's Hospital A. Meyer, Florence; Pediatric Clinic (S.S.), IRCCS Policlinico San Matteo Foundation, University of Pavia, Viale Golgi, Pavia; Department of Pediatric Neurology Unit (B.S.), Buzzi Children's Hospital ASST-FBF-Sacco, Milan; Child Neurology Division (A.S.), Department of Pediatrics, Sapienza University of Rome; Rare and Complex Epilepsy Unit (N.S., M. Trivisano), Department of Neurosciences, Bambino Gesù Children's Hospital, IRCCS; Child Neurology Unit (M.V., F.V.), Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital, IRCCS, Rome; Department of Pediatrics (A. Verrotti), University of Perugia, Italy; and Department of Neurology (I.H.), University of Pennsylvania, Perelman School of Medicine, Philadelphia.

Neurology. Genetics
|June 3, 2022
PubMed
Summary

STXBP1 developmental and epileptic encephalopathy (DEE) shows varied neurodevelopmental outcomes. Later seizure onset in STXBP1-DEE correlates with better development, highlighting epilepsy timing as a key factor.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
297
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
623
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
689